Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAYA: Nivolumab, Ipilimumab, and Temozolomide in MSS MGMT-Silenced mCRC
NCT03832621Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Mar 2019
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in metastatic colorectal cancer (mCRC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: 8-month Progression-Free Survival Rate. Started Mar 2019; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03832621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03832621.